BTK and TEC are specific interactors of dasatinib. DDR1 interacts specifically with nilotinib and dasatinib. Anti-BTK, anti-TEC, and anti-DDR1 immunoblots of K562 pulldown series. Pretreatment was performed by addition of 10 μM parent drug to lysates 30 minutes prior to exposure to drug-affinity matrix. Pretreatment pulldowns were subsequently processed in parallel to regular pulldown experiments. TCL indicates total cell lysate.